You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Gallium 68 Tilmanocept for PET Imaging of Atherosclerosis Plaques

    SBC: Navidea Biopharmaceuticals, Inc.            Topic: NHLBI

    Myocardial infarctionsMIor heart attacksischemic strokesISand peripheral artery diseasePADtogether considered cardiovascular diseaseCVDare all commonly caused by the same underlying pathologyatherosclerosisMIs and ISs are the leading causes of death and disability worldwideAtherosclerosis is a progressive pathology that develops asymptomatically over the course of many years as inflammatory plaque ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  2. High-Throughput Assay for Profiling Alternative Splicing and Splicing Regulators

    SBC: Biospyder Technologies, Inc.            Topic: 172

    SummaryThis Phase I program will develop TempO Splicea highly multiplexed targeted sequencing assay monitoring RNA Binding ProteinRBPsplicing expression and alternatively splicedASmRNA representatives of coregulated splicing modulesa novel variation of the TempO Seqassay used for high throughput screeningdesigned to address the hypothesis that it is possible to provide a surrogate assay of the who ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  3. HUCBC modulation of Alzheimer's-like pathology and behavioral changes

    SBC: SANERON CCEL THERAPEUTICS, INC.            Topic: NIA

    DESCRIPTION (provided by applicant): In the past years, we have shown that human umbilical cord blood cells (HUCBC, U-CORD- CELL ) provide cognitive recovery in animal models of neurodegenerative disease. Infusion of HUCBC resulted in reduced infarct volume as well as in rescue of behavioral benefits in an animal model of stroke. We further showed that HUCBC infusion proved to be beneficial in ani ...

    STTR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health
  4. Identification and Validation of Targets of Phenotypic High Throughput Screening

    SBC: COLLABORATIVE DRUG DISCOVERY, INC.            Topic: NIAID

    DESCRIPTION (provided by applicant): Identification and Validation of Targets of Phenotypic High Throughput Screening Hits for Chagas Disease Project Summary Nearly 10 million people in Latin America are infected with the eukaryotic parasite Trypanosoma cruzi, the causative agent of Chagas disease. The World Health Organization (WHO) classifies Chagas disease as a neglected tropical disease, but C ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  5. Identification of novel therapeutics for tuberculosis combining cheminformatics,

    SBC: COLLABORATIVE DRUG DISCOVERY, INC.            Topic: NIAID

    DESCRIPTION (provided by applicant): This Small Business Technology Transfer Phase I project entitled Identification of novel therapeutics for tuberculosis combining cheminformatics, diverse databases and logic-based pathway analysis describes the development of software that will facilitate new drug discovery efforts for Mycobacterium tuberculosis (TB). The amount of research performed on TB co ...

    STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  6. Integrated Microbial Screening and Antimicrobial Susceptibility Test on Microfluidic Digital Array for Diagnosis of Urinary Tract Infections

    SBC: Combinati Incorporated            Topic: NIAID

    Abstract COMBiNATi will work with Stanford University to bring the world s first integrated ID AST UTI diagnostic platform to the market by combining COMBiNATi sone clickcost effective dPCR platform with Stanford s pathogen identificationIDHRMA algorithm for broad detectiondeep characterization and absolute quantification of UTI pathogensBy the end of the Phaseprojectwe will deliver the prototype ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  7. Internet-based Fidelity Enhancement of MTFC

    SBC: Tfc Consultants, Inc.            Topic: NIMH

    DESCRIPTION (provided by applicant): The proposed project builds upon Phase I proof of concept efforts wherein the basic foundational components of an Internet-based Treatment Fidelity Monitoring System, the ITFMS, were created to assist MTFC consultants and implementing agencies to improve clinical outcomes by moving more efficiently towards and maintaining fidelity of program implementation. I ...

    STTR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health
  8. In Vivo Assessment of Embryonic Stem Cell Teratoma Prevention

    SBC: BIOINVISION INC            Topic: NICHD

    DESCRIPTION (provided by applicant): The capacity to evaluate the teratoma forming potential of differentiated embryonic stem cell populations represents an urgent need before widespread therapeutic application of these cells is possible. Researchers at Case Western Reserve University and BioInVision, Inc. will join together to create platform technologies for validating existing embryonic stem ce ...

    STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  9. In vivo expansion of human hepatocytes in Fah-/-Rag-/-Il2rg-/- mice

    SBC: Yecuris Corporation            Topic: NCRR

    DESCRIPTION (provided by applicant): The liver is the site of many metabolic processes, including metabolism of xenobiotics such as pharmaceutical compounds. Drug metabolism is highly species specific and can vary significantly between individuals of the same species. To date no reliable experimental system capable of predicting the human-specific metabolic conversion of candidate small molecules ...

    STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  10. In Vivo Studies of a Novel HDAC Inhibitor for Treating Hemoglobin Disorders

    SBC: CETYA THERAPEUTICS, INC.            Topic: NHLBI

    PROJECT SUMMARY The β-hemoglobinopathies are prevalent genetic blood diseases with few treatment options. It is estimate that 7% of the worldandapos;s population carries an abnormal hemoglobin gene with 400,000 infants born annually with a severe life threatening hemoglobinopathy. Drug mediated induction of normal, but developmentally silenced, fetal hemoglobin (HbF) expression reduces anemia and ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government